#United States #Rare Diseases #Fort Lee #Kedrion Biopharma #PLGD-1

Kedrion's Advocacy for Rare Disease Awareness

On May 4, Kedrion Biopharma hosted a series of global efforts, both virtual and in-person, designed to highlight Plasminogen Deficiency Type 1 (PLGD-1) as part of Plasminogen Deficiency Awareness Day. This initiative aims to increase public and medical awareness of PLGD-1, a rare genetic disorder that affects approximately 1.6 people per million worldwide.

Understanding PLGD-1

PLGD-1 leads to the abnormal accumulation of fibrin-rich lesions on mucosal surfaces across the body, often resulting in serious complications such as vision impairment, hearing loss, airway blockages, recurring infections, and issues with fertility. One of the biggest challenges that patients with this condition face is misdiagnosis due to its similarities with more common ailments, contributing to significant delays in receiving appropriate treatment.

The observance of Plasminogen Deficiency Awareness Day emphasizes the vital need for increased understanding of this condition, which is frequently overlooked. Kedrion’s goal is not only to promote earlier recognition of symptoms but also to encourage timely diagnostic testing, which is crucial to improve the outcomes for individuals living with PLGD-1.

The Event

This year’s events featured several key components, including remarks from Kedrion’s leadership, insights from seasoned physicians specializing in symptom recognition, and contributions from patient advocacy organizations. The program highlighted interactive discussions with both patients and caregivers, demonstrating the real-world impacts of delays in diagnosis and underscoring the need for collaborative efforts to improve awareness and testing pathways.

Bob Rossilli, Chief Commercial Officer at Kedrion, stated: “Plasminogen Deficiency Awareness Day underscores the importance of collective action in addressing rare and ultra-rare diseases. Working closely with the medical community and patient advocacy bodies, we aim to elevate awareness of PLGD-1 and facilitate earlier diagnoses.” This collaborative approach is essential to shorten the diagnostic journey and to enhance the quality of life for individuals affected by this condition.

Advocacy and Education

Advocacy leaders participating in the event stressed the need for ongoing education to reduce diagnostic delays, which can, in some cases, stretch over several years. Dr. Rebecca Bialas, co-founder of the Plasminogen Deficiency Foundation and a mother of two children suffering from this condition, emphasized the power of awareness in garnering hope and progress for families affected by PLGD-1. “Seeing our community gain visibility year after year is incredibly inspiring,” she said. “Kedrion's consistent efforts in education and providing access to resources make a tangible difference for those who have waited too long for support.”

Pamela Gavin, CEO of the National Organization for Rare Disorders (NORD), shared crucial insights about the lengthy period patients with rare diseases often endure while seeking an accurate diagnosis. She highlighted that, through enhanced awareness, improved clinician education, and access to specialists, the process of identifying such diseases can be expedited, ultimately improving the overall quality of life for patients and their families.

Call to Action

Despite the lengthy and complex journey for diagnosis, PLGD-1 can be identified through straightforward laboratory tests. As of now, fewer than 100 cases have officially been documented in the United States. However, estimates suggest that the actual number may be significantly higher due to underreporting. Thus, it is imperative to raise awareness amongst both healthcare professionals and the public to ensure quicker diagnoses and appropriate treatment.

The symptoms of PLGD-1 often manifest as chronic or recurrent inflammatory states that do not respond well to conventional treatments. By raising awareness about the red flags associated with PLGD-1, as highlighted on Awareness Day, both patients and healthcare providers can consider appropriate testing, leading to more timely care.

To discover more about Plasminogen Deficiency Type 1 and ways to support awareness efforts, please visit Plasminogen.info. Kedrion Biopharma is dedicated to creating a world where science and patient care are intertwined without barriers, working closely with the medical-scientific community, institutions, and patient advocacy groups to foster innovation and enhance care.

About Kedrion Biopharma

Kedrion Biopharma specializes in collecting and fractionating blood plasma to produce and distribute therapies for various rare and ultra-rare debilitating conditions. With a workforce of over 5,400 individuals and a robust industrial network that includes numerous plasma collection centers and production facilities across multiple countries, Kedrion is firmly committed to advancing patient care and awareness.

Through its dedicated initiative "Rare but Real," Kedrion seeks to shed light on the stories of people living with rare diseases, sharing narratives that help to increase understanding and visibility across digital platforms like Instagram and YouTube.